ClinicalTrials.gg
CompletedNCT07596173Updated Sep 9, 2026

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years

A Phase 3 interventional study of dTpa vaccine in Diphtheria-Tetanus-acellular Pertussis Vaccines, sponsored by GlaxoSmithKline. Completed at 10 sites in Japan. Open to participants aged 11 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
11 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 101 studies in Diphtheria by GlaxoSmithKline — none open to participants now, 1 under way, 1 of them phase 3. Diphtheria · GlaxoSmithKline.

Enrollment
82nd of 92
90 · median 450
Started
2026
with 1 other
Phase 3
55 of 101
none open now
Registered
100th of 101
by date

Among the 101 studies in Diphtheria by GlaxoSmithKline, this one is the 82nd largest by enrollment of the 92 interventional ones that give a count, is one of 2 that started in 2026, is one of 55 in phase 3, and was the 100th registered.

Diphtheria

268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.

Browse Diphtheria studies →

Open to participants now

None of the 101 studies in Diphtheria by GlaxoSmithKline is open now. The open studies under Diphtheria, anywhere →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 11 Years to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies in Diphtheria by GlaxoSmithKline as a file.
02

Study summary

The purpose of the study is to assess the immune response, reactogenicity and safety of a booster dose of dTpa vaccine 1 month after vaccination in healthy Japanese participants aged 11 to \<13 years.

03

Conditions studied

  • Diphtheria-Tetanus-acellular Pertussis Vaccines

Keywords

  • Diphtheria tetanus and acellular pertussis (dTpa) vaccine
  • Adolescent
  • Immune response
  • Reactogenicity
  • Safety
04

Who can participate

Ages eligible
11 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants and/or participants' parent(s)/ Legally acceptable representative(s) [LAR(s)], who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Physical or digital informed assent obtained from the participant prior to performance of any study-specific procedure.
  • Physical or digital obtained from the parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
  • Healthy participants as established by medical history and clinical examination at screening.
  • Male/female participant between and including 11 and \<13 years of age at the time of the study intervention administration (Visit 1/Day 1).
  • Previously completed all routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s). Participants with documented previous diphtheria, tetanus and pertussis vaccination (primary series and first booster) as per routine vaccination in Japan prior to study enrolment.
  • Participants did not receive an additional diphtheria, tetanus with or without pertussis vaccination within 5 years prior to enrolment in the study.
  • Japanese ethnic origin.
  • Participants of non- may be enrolled in the clinical study.
  • Participant of childbearing potential may be enrolled in the study if the participant:
  • has practiced adequate for at least 30 days prior to study intervention administration, and
  • has a negative pregnancy test within 24 hours prior to the study intervention administration, and
  • has agreed to continue adequate contraception during the entire treatment period and for 8 weeks after completion of the study intervention administration series.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • History of physician-diagnosed or laboratory-confirmed diphtheria, tetanus or pertussis diseases within the past 5 years.
  • History of encephalopathy after administration of a previous dose of pertussis vaccine that could not be attributed to another identifiable cause, progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy: pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized.
  • History of transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria and/or tetanus.
  • History of any reaction or likely to be exacerbated by any component of the study intervention(s) or having shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination
  • Acute or unstable chronic conditions pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
  • Condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any or non-registered product other than the study intervention(s) during the period beginning 30 days before the dose of study intervention(s), or their planned use during the study period.
  • Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.
  • Chronic administration of immune-modifying drugs and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.

    • Up to 6 months prior to the study intervention administration:

For , this will mean prednisone equivalent ³0.5 mg/kg/day with maximum of 20 mg/day. Inhaled, intra-articular/intra-bursal and topical steroids are allowed.

  • Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy, monoclonal antibodies, antitumoral medication.

    • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the dose and ending 30 days after the dose of study intervention(s) administration*, with the exception of inactivated influenza vaccine and SARS-CoV-2 vaccine which can be given at any time during the study conduct.

      *If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided it is used according to the local governmental recommendations and Sponsor is notified.

    • Planned administration of any prophylactic medication in the absence of any symptom and in anticipation of a reaction to the study intervention administration.

Prior/Concurrent clinical study participation

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention vaccine/drug/invasive medical device.

Other exclusion criteria

  • Pregnant or lactating participant.
  • History of /current chronic alcohol consumption and/or drug abuse, based on investigator's judgment.
  • Any study personnel or their immediate dependents, family, or household members.
  • Child in care.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    dTpa Group

    Participants aged 11 to less than (\<) 13 years receive the dTpa vaccine at Day 1.

    Biological: dTpa vaccine

Interventions

  • BiologicaldTpa vaccine

    Combined reduced antigen content diphtheria, tetanus and acellular pertussis (dTpa) vaccine administered at Day 1.

06

What researchers measure

Primary outcomes

  1. Number of seropositive participants for anti-pertussis toxin (anti-PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies

    Seropositivity is defined as antibody concentrations (anti-PT, anti-FHA and anti-PRN) are greater than or equal to the assessed assay cut-offs. The considered cut-off values are: anti-PT: 2.693 International Units per milliliter (IU/mL), anti-FHA: 2.046 IU/mL, anti-PRN: 2.187 IU/mL, as measured by Enzyme-Linked Immunosorbent assay (ELISA).

    Time frame: 1 month after vaccination

  2. Number of seroprotected participants for anti-diphteria and anti-tetanus antibodies

    Seroprotection is defined as anti-diphtheria and anti- tetanus antibody concentrations being \>=0.1 IU/mL as measured by ELISA.

    Time frame: 1 month after vaccination

Secondary outcomes

  1. Number of participants with booster-response to pertussis (PT, FHA and PRN) antigens

    Booster response to PT, FHA and PRN antigens is defined as: for participants with pre-vaccination antibody concentration below the assay cut-off, post-vaccination antibody concentration \>=4 times the assay cut-off; for participants with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off, post-vaccination antibody concentration \>= 4 times the pre-vaccination antibody concentration; for participants with pre-vaccination antibody concentration \>=4 times the assay cut-off, post-vaccination antibody concentration \>=2 times the pre-vaccination antibody concentration.

    Time frame: 1 month after vaccination

  2. Antibody concentration against pertussis (PT, FHA, PRN) antigens

    Time frame: At baseline (Day 1) and 1 month after vaccination

  3. Antibody concentration for anti-diphtheria and anti-tetanus antibodies

    Time frame: At baseline (Day 1) and 1 month after vaccination

  4. Number of participants with solicited local adverse events (AEs)

    Solicited local AEs are pain, redness (erythema) and swelling at administration site.

    Time frame: From Day 1 (day of vaccination) to Day 7 post-vaccination

  5. Number of participants with solicited systemic AEs

    Solicited systemic AEs are fever, headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness) and gastrointestinal symptoms.

    Time frame: From Day 1 (day of vaccination) to Day 7 post-vaccination

  6. Number of participants with unsolicited AEs

    An unsolicited AE is an AE that was either not included in the list of solicited AEs or could be included in the list of solicited AEs but with an onset outside the specified period of follow-up for solicited AEs. Unsolicited AEs include both serious and non-serious AEs.

    Time frame: From Day 1 (day of vaccination) to Day 30 post-vaccination

  7. Number of participants with serious AEs (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes, is a suspected transmission of any infectious agent via an authorized medicinal product, or other situations as per investigator's judgment.

    Time frame: From Day 1 (day of vaccination) to Day 30 post-vaccination

  8. Number of participants with AEs leading to study withdrawal

    Time frame: From Day 1 (day of vaccination) to Day 30 post-vaccination

07

Study locations

10 sites
  • GSK Investigational Site
    Fukuoka, 812-0871, Japan
  • GSK Investigational Site
    Hokkaido, 004-0052, Japan
  • GSK Investigational Site
    Hokkaido, 006-0814, Japan
  • GSK Investigational Site
    Hokkaido, 062-0907, Japan
  • GSK Investigational Site
    Kumamoto, 862-0924, Japan
  • GSK Investigational Site
    Mie, 511-0865, Japan
  • GSK Investigational Site
    Osaka, 554-0014, Japan
  • GSK Investigational Site
    Saitama, 337-0042, Japan
  • GSK Investigational Site
    Saitama, 360-0812, Japan
  • GSK Investigational Site
    Shizuoka, 420-8623, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Sep 2026, 2 months.

Of 47 industry-sponsored phase 3 interventional studies under Diphtheria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 2 months is below that.

Counting every sponsor, half of 47 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
May 19, 2026
StartActual
Jun 29, 2026
Primary completionActual
Sep 4, 2026
CompletionActual
Sep 4, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07596173
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Jun 29, 2026
Primary completion
Sep 4, 2026
Completion
Sep 4, 2026
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion